Guselkumab dosing interval optimization in adult patients with moderate‐to‐severe psoriasis switching from ustekinumab

Abstract

Psoriasis (PSO) is an inflammatory disease that emerges as a dysregulation of the interleukin 23 (IL23)/Th17 axis. There are many biologic alternatives to treat PSO that are administered monthly, every 2 months and every 3 months. Guselkumab (GUS) is a fully human monoclonal antibody, that selectively blocks IL-23 through binding to its p19 subunit. There is scarce evidence on dose optimization of GUS in psoriatic patients. Retrospective, observational case series review which includes patients with moderate-to-severe PSO who switched from ustekinumab to GUS as standard dosing or every 12 weeks, regarding daily clinical practice of every dermatology unit. Clinical and demographic data from patients were included from February 2019 to October 2021. Analyses were performed "as observed" using GraphPad Prism version 8.3.0 for Windows (GraphPad Software,

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

“…Furthermore, in VOYAGE 1, PASI 75 and PASI 90 were 76.3% and 87.8%, respectively, at 48 weeks. Similar outcomes were obtained in our study, where 88% of patients Our findings are also consistent with other real-life guselkumab studies [12,[15][16][17][18][19]. For example, an Italian study that had a mean ± SD baseline PASI score of 15.1 ± 6.1 showed that PASI 75, 90, and 100 were achieved by 95.6%, 73.9%, and 43.5% of patients at 44 weeks, respectively Likewise, our study achieved PASI 75, 90, and 100 in 88%, 72%, and 48% of patients at 52 weeks, respectively.…”

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)

“…Our retrospective study is one of the largest real‐life studies on guselkumab use in patients who failed ustekinumab, with a population of 233 patients. Our study confirmed data from both clinical trials and real‐life studies on the effectiveness of guselkumab in daily clinical practice in patients affected by moderate‐to‐severe plaque psoriasis with previous exposure to ustekinumab 12,14,16,17 . Compared with the Phase 3 clinical trial NAVIGATE, 12 which evaluated the effectiveness of guselkumab in patients with inadequate response to ustekinumab in 135 patients, our cohort was larger at baseline.…”

“…Our study confirmed data from both clinical trials and real-life studies on the effectiveness of guselkumab in daily clinical practice in patients affected by moderate-to-severe plaque psoriasis with previous exposure to ustekinumab. 12,14,16,17 Compared with the Phase 3 clinical trial NAVIGATE, 12 which evaluated the effectiveness of guselkumab in patients with inadequate response to ustekinumab in 135 patients, our cohort was larger at baseline. Our population was slightly older (with a mean age of 54.27 years vs. 44.2 years), with a lower BMI (27.56 vs. 30.3) and also included patients with previous exposure to anti-IL-17 drugs.…”

“…These findings are consistent with other real-life studies which evaluated the effectiveness of guselkumab in a cohort of multi-failure patients (including patients with previous exposure to anti-IL-17 drugs). 14,16,17,27,28 Guselkumab, along with other anti-IL-23 drugs, could also represent a valid therapeutic option in patients who failed several biologics.…”

A Successful Switch From Ustekinumab to an Extended Dosing Interval of Guselkumab Without Induction in a Patient With Psoriasis Vulgaris

“…Notably, the mean baseline PASI score at the time of switching was 3.55, considerably lower than that of the standard care group (14.53) [10]. Furthermore, a phase 2 trial of GUS indicated that a dose of GUS 50 mg Q12W was effective even with a high baseline PASI score [11].…”